Federal Register / Vol. 81, No. 26 / Tuesday, February 9, 2016 / Notices 6877 

Comment Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30 days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, or request more 

information on the proposed project, 

contact: Charles Hall, RPh, M.S., Chief, 

Pharmaceutical Management Branch, 

Cancer Therapy Evaluation Program, 

National Cancer Institute, 9609 Medical 

Center Drive, RM 5W240, MSC 9725, 

Bethesda, Maryland 20892. Or call nontoll-free number (240) 276–6575, or 

email your request, include your 

address to: hallch@mail.nih.gov. 

Formal requests for additional plans 

and instruments must be requested in 

writing. 

Proposed Collection: Drug 

Accountability Report Form and 

Investigator Registration Procedure in 

the Conduct of Investigational Trials for 

the Treatment of Cancer, 0925–0613, 

Expiration Date 03/31/2016, Revision, 

National Cancer Institute (NCI), 

National Institutes of Health (NIH). 

Need and Use of Information 

Collection: The U.S. Food and Drug 

Administration (FDA) holds the 

National Cancer Institute (NCI) 

responsible, as a sponsor of 

investigational drug trials, for the 

collection of information about the 

clinical investigators who participate in 

these trials and to assure the FDA that 

systems for accountability are being 

maintained by investigators in its 

clinical trials program. The information 

collected is used to identify qualified 

investigators and to facilitate the 

submission and distribution of 

important information relative to the 

investigational drug and the response of 

the patient to that drug. Investigators are 

physicians who specialize in the 

treatment of patients with cancer. Data 

obtained from the Drug Accountability 

Record is used to track the dispensing 

of investigational anticancer agents from 

receipt from the NCI to dispensing or 

administration to patients. NCI and/or 

its auditors use this information for 

compliance purposes. The frequency of 

Response is up to 16 times per year. The 

affected public is private sector 

including businesses, other for-profit 

organizations, and non-profit 

institutions. The type of respondents are 

investigators, pharmacists, nurses, 

pharmacy technicians, and data 

managers. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

14,649 hours. 

TABLE 1—ESTIMATES OF ANNUAL BURDEN

Estimated annualized burden hours 

Type of 

respondents Form Number of respondents 

Number of 

responses 

Average time 

per response 

(in hours) 

Total hour 

burden 

Investigators and Designee for Investigator Registration and DARF.Statement of Investigator ................. 22,283 1 15/60 5,571 

NCI/DCTD/CTEP Supplemental Investigator.22,283 1 10/60 3,714 

Financial Disclosure Forms .............. 22,283 1 5/60 1,857 

NCI/DCTD/CTEP Drug Accountability Record Form (DARF and 

DARF-Oral).

3,288 16 4/60 3,507 

Total ........................................... ........................................................... 25,571 119,457 ........................ 14,649 

Dated: February 3, 2016. 

Karla Bailey, 

Project Clearance Liaison, National Cancer 

Institute, NIH. 

[FR Doc. 2016–02447 Filed 2–8–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NST1 Member Conflict SEP. 

Date: March 8, 2016. 

Time: 9:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Arlington, 1325 Wilson 

Boulevard, Arlington, VA 22209. 

Contact Person: William C Benzing, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

0660, benzingw@mail.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NINDS R 35 Review. 

Date: March 17–18, 2016. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Natalia Strunnikova, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Research, NINDS/NIH/DHHS/Neuroscience 

Center, 6001 Executive Boulevard, Suite 

3208, MSC 9529, Bethesda, MD 20892–9529, 

301–402–0288, Natalia.strunnikova@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NINDS R35 Review. 

Date: March 17–18, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Ernest W Lyons, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

4056, lyonse@ninds.nih.gov. 

mstockstill on DSK4VPTVN1PROD with NOTICES

6878 Federal Register / Vol. 81, No. 26 / Tuesday, February 9, 2016 / Notices 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; NINDS R35 Review. 

Date: March 17–18, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Birgit Neuhuber, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

3562, neuhuber@ninds.nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; R24/P30 Review. 

Date: April 5, 2016. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: Natalia Strunnikova, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Division of Extramural 

Research, NINDS/NIH/DHHS/Neuroscience 

Center, 6001 Executive Boulevard, Suite 

3208, MSC 9529, Bethesda, MD 20892–9529, 

301–402–0288, Natalia.strunnikova@nih.gov. 

Name of Committee: National Institute of 

Neurological Disorders and Stroke Special 

Emphasis Panel; Udall Center Review. 

Date: April 5–6, 2016. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hotel Monaco Alexandria, 480 King 

Street, Alexandria, VA 22314. 

Contact Person: Birgit Neuhuber, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Division of Extramural Research, 

NINDS/NIH/DHHS/Neuroscience Center, 

6001 Executive Boulevard, Suite 3208, MSC 

9529, Bethesda, MD 20892–9529, 301–496– 

3562, neuhuber@ninds.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: February 4, 2016. 

Sylvia Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–02536 Filed 2–8–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; ‘‘Comprehensive Resources 

for HIV Microbicides and Biomedical 

Prevention (N01)’’. 

Date: February 23, 2016. 

Time: 8:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, Room 

3F100, 5601 Fishers Lane, Rockville, MD 

20892, (Telephone Conference Call). 

Contact Person: Jay R Radke, Ph.D., AIDS 

Review Branch, Scientific Review Program, 

Division of Extramural Activities, Room 

#3G11B, National Institutes of Health, NIAID, 

5601 Fishers Lane MSC–9823, Bethesda, MD 

20892–9823, (240) 669–5046, jay.radke@

nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 4, 2016. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2016–02535 Filed 2–8–16; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group; Chemo/Dietary Prevention Study 

Section. 

Date: February 25, 2016. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 

Contact Person: Svetlana Kotliarova, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

Bethesda, MD 20892, 301–594–7945, 

kotliars@mail.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: AIDS and Related 

Research Integrated Review Group; AIDS 

Molecular and Cellular Biology Study 

Section. 

Date: March 2, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: San Diego Marriott Mission Valley 

Hotel, 8757 Rio San Diego Drive, San Diego, 

CA 92108. 

Contact Person: Kenneth A Roebuck, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5214, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1166, roebuckk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR Panel: 

Health Disparities in and Caregiving for 

Alzheimer’s Disease. 

Date: March 4, 2016. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Wardman Park Washington 

DC Hotel, 2660 Woodley Road NW., 

Washington, DC 20008. 

Contact Person: Gabriel B Fosu, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3108, 

MSC 7808, Bethesda, MD 20892, (301) 435– 

3562, fosug@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Reproduction, Endocrinology and Metabolic 

Processes. 

mstockstill on DSK4VPTVN1PROD with NOTICES